...
首页> 外文期刊>Malaria Journal >Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique
【24h】

Impact of age of first exposure to Plasmodium falciparum on antibody responses to malaria in children: a randomized, controlled trial in Mozambique

机译:首次接触恶性疟原虫的年龄对儿童对疟疾的抗体反应的影响:莫桑比克的一项随机对照试验

获取原文

摘要

Background The impact of the age of first Plasmodium falciparum infection on the rate of acquisition of immunity to malaria and on the immune correlates of protection has proven difficult to elucidate. A randomized, double-blind, placebo-controlled trial using monthly chemoprophylaxis with sulphadoxine-pyrimethamine plus artesunate was conducted to modify the age of first P. falciparum erythrocytic exposure in infancy and assess antibodies and malaria risk over two years. Methods Participants (n?=?349) were enrolled at birth to one of three groups: late exposure, early exposure and control group, and were followed up for malaria morbidity and immunological analyses at birth, 2.5, 5.5, 10.5, 15 and 24 months of age. Total IgG, IgG subclasses and IgM responses to MSP-119, AMA-1, and EBA-175 were measured by ELISA, and IgG against variant antigens on the surface of infected erythrocytes by flow cytometry. Factors affecting antibody responses in relation to chemoprophylaxis and malaria incidence were evaluated. Results Generally, antibody responses did not vary significantly between exposure groups except for levels of IgM to EBA-175, and seropositivity of IgG1 and IgG3 to MSP-119. Previous and current malaria infections were strongly associated with increased IgG against MSP-119, EBA-175 and AMA-1 (p?
机译:背景已证明难以阐明首次恶性疟原虫感染的年龄对获得疟疾免疫力的速率以及对保护免疫相关因子的影响。进行了一项随机,双盲,安慰剂对照试验,使用每月化学预防用磺胺多辛-乙胺嘧啶加青蒿琥酯进行化学治疗,以改变婴儿期首次恶性疟原虫红细胞暴露的年龄,并评估两年内抗体和疟疾的风险。方法参与者(n?=?349)在出生时被分为三组之一:晚期暴露,早期暴露和对照组,并在出生后分别接受2.5、5.5、10.5、15和24的疟疾发病率和免疫学分析。月龄。通过ELISA测定了对MSP-119,AMA-1和EBA-175的总IgG,IgG亚类和IgM反应,并通过流式细胞仪检测了针对被感染红细胞表面抗原的IgG。评价了与化学预防和疟疾发病率相关的抗体反应影响因素。结果通常,暴露组之间的抗体反应没有显着差异,除了对EBA-175的IgM水平和对MSP-119的IgG1和IgG3的血清阳性。先前和当前的疟疾感染与针对MSP-119,EBA-175和AMA-1的IgG升高密切相关(p 0.0001)。调整暴露量后,只有更高水平的抗EBA-175 IgG与降低的临床疟疾发病率显着相关(IRR 0.67,p?=?0.0178)。结论总体而言,首次恶性疟原虫感染的年龄并未影响IgG反应的强度和广度,但先前的暴露对于抗体的获取至关重要。 IgG对EBA-175的反应是针对临床疟疾的最强保护作用。试用注册ClinicalTrials.gov:NCT00231452。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号